147 related articles for article (PubMed ID: 30742560)
1. A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma.
Adams HJA; Kwee TC
J Clin Oncol; 2019 Apr; 37(10):852-853. PubMed ID: 30742560
[No Abstract] [Full Text] [Related]
2. Brentuximab vedotin.
Younes A; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Jan; 11(1):19-20. PubMed ID: 22212672
[No Abstract] [Full Text] [Related]
3. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.
Nathwani N; Krishnan AY; Huang Q; Kim Y; Karanes C; Smith EP; Forman SJ; Sievers E; Thomas SH; Chen RW
Leuk Lymphoma; 2012 Oct; 53(10):2051-3. PubMed ID: 22369501
[No Abstract] [Full Text] [Related]
4. Expression of CD30 as a biomarker to predict response to brentuximab vedotin.
Xu ML; Acevedo-Gadea C; Seropian S; Katz SG
Histopathology; 2016 Jul; 69(1):155-8. PubMed ID: 26648051
[No Abstract] [Full Text] [Related]
5. Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.
Wang Y; Wang Z; Wei C; Zhao D; Zhang Y; Wang W; Zhang W; Zhou D
Ann Hematol; 2023 Oct; 102(10):2973-2975. PubMed ID: 37522969
[No Abstract] [Full Text] [Related]
6. Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.
Moore DC; Elmes JB; Strassels SA; Patel JN
Leuk Lymphoma; 2022 Jul; 63(7):1768-1769. PubMed ID: 35249444
[No Abstract] [Full Text] [Related]
7. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
Shanbhag S; Prasad V
Eur J Cancer; 2018 Nov; 104():252-253. PubMed ID: 30342911
[No Abstract] [Full Text] [Related]
8. Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment.
Dubbini MV; De Marco L; Baldi L; Vignolo L; Ilariucci F
Leuk Lymphoma; 2023; 64(8):1497-1499. PubMed ID: 37282612
[No Abstract] [Full Text] [Related]
9. The optimal regimen of brentuximab vedotin for CD30
Geller S; Myskowski PL; Kim YH; Moskowitz A; Horwitz S
Br J Dermatol; 2018 Feb; 178(2):571. PubMed ID: 29023638
[No Abstract] [Full Text] [Related]
10. Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.
Costa PA; Espejo-Freire AP; Fan KC; Albini TA; Pongas G
Leuk Lymphoma; 2022 Jan; 63(1):239-242. PubMed ID: 34514943
[No Abstract] [Full Text] [Related]
11. Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven.
Adams HJA; Kwee TC
Blood; 2018 Jul; 132(3):339-340. PubMed ID: 29858234
[No Abstract] [Full Text] [Related]
12. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
13. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
14. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
15. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
17. Is CD30 a predictive biomarker for brentuximab vedotin?
Chen R
Leuk Lymphoma; 2017 Jul; 58(7):1524-1525. PubMed ID: 28278730
[No Abstract] [Full Text] [Related]
18. [Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin].
Cai MC; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):81-86. PubMed ID: 36987732
[No Abstract] [Full Text] [Related]
19. Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma.
Engelina S; Saggu M; Yoo J; Shah F; Stevens A; Irwin C; Chaganti S; Scarisbrick JJ
Br J Dermatol; 2020 Mar; 182(3):799-800. PubMed ID: 31529492
[No Abstract] [Full Text] [Related]
20. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
Parker C; Woods B; Eaton J; Ma E; Selby R; Benson E; Engstrom A; Sajosi P; Briggs A; Bonthapally V
J Med Econ; 2017 Jan; 20(1):8-18. PubMed ID: 27472034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
